Skip to main content
. 2021 Aug 1;60(15):2367–2374. doi: 10.2169/internalmedicine.6127-20

Table 2.

Comparison of Variables between Baseline and 6 Months after the Administration of Dapagliflozin.

Baseline 6 months p value
Clinical Characteristics
Body weight (kg) 66.5 (56.8-76.9) 63.9 (56.2-75.6) <0.001
BMI (kg/m2) 25.3 (23.4-28.8) 24.9 (22.8-27.8) <0.001
Systolic blood pressure (mmHg) 130±16 128±18 0.218
Heart rate (bpm) 71±12 70±11 0.610
BNP (pg/mL) 27.9 (9.0-58.2) 28.9 (9.6-62.9) 0.132
BUN (mg/dL) 14.7 (12.1-19.0) 17.2 (14.2-21.2) <0.001
Creatinine (mg/dL) 0.80±0.20 0.86±0.23 <0.001
eGFR (mL/min/1.73 m2) 70.6±17.0 65.6±15.3 0.001
HbA1c (%) 7.2±0.8 7.0±0.8 0.108
Hemoglobin (g/dL) 13.7±1.7 14.4±1.6 0.020
Hematocrit (%) 41.0±4.7 43.8±4.5 0.002
Lipid profiles (mg/dL)
Triglycerides 127 (84-185) 116 (82-176) 0.155
LDL cholesterol 98 (86-118) 106 (89-126) 0.078
HDL cholesterol 51.5 (45.0-60.2) 52 (42.8-65.0) 0.049
Uric acid (mg/dL) 5.1 (4.4-5.9) 4.7 (4.2-5.7) 0.057
Echocardiographic Parameters
LV end-diastolic volume (mL) 74.2 (55.1-104.1) 68.5 (54.8-93.8) 0.270
LV end-systolic volume (mL) 24.7 (17.0-54.5) 20.5 (15.2-57.1) 0.105
LVEF (%) 62.3 (49.3-68.3) 63.6 (55.3-71.0) 0.011
LVMI (g/m2) 75.0 (61.7-92.0) 67.0 (55.0-81.9) <0.001
LAVI (mL/m2) 31 (23-45) 26 (21-32) 0.001
e’ (cm/s) 6.36±1.73 6.82±1.88 0.031
E/e’ 9.3 (7.7-11.8) 8.5(6.6-10.7) 0.020
E (cm/s) 58.1 (46.8-70.9) 55.1 (45.3-73.7) 0.682
A (cm/s) 76.1±17.8 75.6±16.8 0.765
E/A 0.71 (0.6-0.80) 0.70 (0.62-0.81) 0.818

Data are mean±SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%). BNP: plasma brain natriuretic peptide, LDL: low density lipoprotein, HDL: high density lipoprotein, LVMI: left ventricular mass index, LVEF: left ventricular ejection fraction, LAVI: left atrial volume index, E: peak early diastolic mitral flow velocity, e’: spectral pulsed-wave Doppler-derived early diastolic velocity from the septal mitral annulus